Among all the pharmacologic therapies available for second-line treatment for T2D, glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) are particularly gaining popularity owing to their well-established hypoglycemic efficacy, significant remission rate of complications, and reliable benefits such as weight loss [3, 6]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.